388 related articles for article (PubMed ID: 33465137)
1. The coronavirus proofreading exoribonuclease mediates extensive viral recombination.
Gribble J; Stevens LJ; Agostini ML; Anderson-Daniels J; Chappell JD; Lu X; Pruijssers AJ; Routh AL; Denison MR
PLoS Pathog; 2021 Jan; 17(1):e1009226. PubMed ID: 33465137
[TBL] [Abstract][Full Text] [Related]
2. Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations.
Graepel KW; Lu X; Case JB; Sexton NR; Smith EC; Denison MR
mBio; 2017 Nov; 8(6):. PubMed ID: 29114026
[TBL] [Abstract][Full Text] [Related]
3. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
[TBL] [Abstract][Full Text] [Related]
4. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2.
Ogando NS; Zevenhoven-Dobbe JC; van der Meer Y; Bredenbeek PJ; Posthuma CC; Snijder EJ
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938769
[TBL] [Abstract][Full Text] [Related]
5. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.
Smith EC; Blanc H; Surdel MC; Vignuzzi M; Denison MR
PLoS Pathog; 2013 Aug; 9(8):e1003565. PubMed ID: 23966862
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target.
Tahir M
J Med Virol; 2021 Jul; 93(7):4258-4264. PubMed ID: 33837972
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic Processing of the Coronavirus Replicase Nonstructural Protein 14 Exonuclease Is Not Required for Virus Replication but Alters RNA Synthesis and Viral Fitness.
Anderson-Daniels J; Gribble J; Denison M
J Virol; 2022 Aug; 96(16):e0084122. PubMed ID: 35924922
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule Antiviral β-d-
Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
[TBL] [Abstract][Full Text] [Related]
9. Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate Immunity.
Case JB; Li Y; Elliott R; Lu X; Graepel KW; Sexton NR; Smith EC; Weiss SR; Denison MR
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046453
[TBL] [Abstract][Full Text] [Related]
10. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2.
Saramago M; Bárria C; Costa VG; Souza CS; Viegas SC; Domingues S; Lousa D; Soares CM; Arraiano CM; Matos RG
FEBS J; 2021 Sep; 288(17):5130-5147. PubMed ID: 33705595
[TBL] [Abstract][Full Text] [Related]
11. Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelity.
Smith EC; Case JB; Blanc H; Isakov O; Shomron N; Vignuzzi M; Denison MR
J Virol; 2015 Jun; 89(12):6418-26. PubMed ID: 25855750
[TBL] [Abstract][Full Text] [Related]
12. High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants.
Eckerle LD; Lu X; Sperry SM; Choi L; Denison MR
J Virol; 2007 Nov; 81(22):12135-44. PubMed ID: 17804504
[TBL] [Abstract][Full Text] [Related]
13. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
Narayanan N; Nair DT
Int J Biol Macromol; 2021 Jan; 168():272-278. PubMed ID: 33309661
[TBL] [Abstract][Full Text] [Related]
14. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN.
Moeller NH; Shi K; Demir Ö; Belica C; Banerjee S; Yin L; Durfee C; Amaro RE; Aihara H
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35165203
[TBL] [Abstract][Full Text] [Related]
15. Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors.
Riccio AA; Sullivan ED; Copeland WC
J Biol Chem; 2022 Jan; 298(1):101518. PubMed ID: 34942146
[TBL] [Abstract][Full Text] [Related]
16. Fitness Barriers Limit Reversion of a Proofreading-Deficient Coronavirus.
Graepel KW; Agostini ML; Lu X; Sexton NR; Denison MR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341046
[TBL] [Abstract][Full Text] [Related]
17. Analysis of critical protein-protein interactions of SARS-CoV-2 capping and proofreading molecular machineries towards designing dual target inhibitory peptides.
Arabi-Jeshvaghani F; Javadi-Zarnaghi F; Ganjalikhany MR
Sci Rep; 2023 Jan; 13(1):350. PubMed ID: 36611052
[TBL] [Abstract][Full Text] [Related]
18. Homology-Based Identification of a Mutation in the Coronavirus RNA-Dependent RNA Polymerase That Confers Resistance to Multiple Mutagens.
Sexton NR; Smith EC; Blanc H; Vignuzzi M; Peersen OB; Denison MR
J Virol; 2016 Aug; 90(16):7415-7428. PubMed ID: 27279608
[TBL] [Abstract][Full Text] [Related]
19. Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response.
Becares M; Pascual-Iglesias A; Nogales A; Sola I; Enjuanes L; Zuñiga S
J Virol; 2016 Jun; 90(11):5399-5414. PubMed ID: 27009949
[TBL] [Abstract][Full Text] [Related]
20. Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex.
Deval J; Gurard-Levin ZA
Molecules; 2022 May; 27(9):. PubMed ID: 35566268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
